Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in autoimmune premature ovarian insufficiency
2017-004532-10Phase 2Active
- Sponsor
- Karolinska University Hospital
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rituximab in autoimmune premature ovarian insufficiency and gonadal failure, sponsored by Karolinska University Hospital. Primary endpoint: Adverse events. Started Jan 2018; status: active.
02
Drugs
rituximab
03
Conditions
autoimmune premature ovarian insufficiencygonadal failure
Beyond the preview
Go deeper on 2017-004532-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004532-10.